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Abstract
Background: Iron is a vital constituent of cells but in excess may be harmful and
is associated with a raised risk for some malignant diseases including breast cancer.
We aimed to study changes in iron profile in Sudanese females newly diagnosed with
breast cancer.Methods: A case- control study in which serum iron, Total Iron Binding
Capacity (TIBC), and transferrin saturation percent were measured for fifty females
with breast cancer referred to Khartoum Oncology Hospital and seventy apparently
healthy females, using manual method (IRON-FERROZINE). Results: Mean age was
47 years and 42 years in cases and control, respectively and the mean of parity was
4 in both groups. Mean of serum iron ±SD in case group was 244.30 ± 151.598(𝜇g/dL)
and in control group was 57.59 ± 43.191(𝜇g/dL) (P. value = 0.000). Mean of TIBC ±SD
in cases was 412.98 ± 177.460(𝜇g/dL) and in controls it was 403.71 ± 168.765(𝜇g/dL)
(P. value = 0.838). The mean of transferrin saturation percent ± SD in cases was 61.08
% ±41.523 and in controls was 223.23 % ±149.195 (P. value=0.000). The mean of TIBC
in grade I 343.00(𝜇g/dL), 467.10(𝜇g/dL) in grade II and 321.25(𝜇g/dL) in grade III (P.
value 0.019) according to Modified Bloom Richardson’s grading system. Conclusion:
There is a statistically significant increase in the mean of serum iron and decrease
in transferrin saturation percent in women with breast cancer. TIBC vary significantly
according to histopathological grade. Serum iron and transferrin saturation percent
may be helpful as biochemical risk markers for breast cancer and TIBC may act as a
predictor of disease grade.
Keywords: Iron profile, serum iron, TIBC, Transferrin saturation percent, breast cancer,
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1. Introduction
Breast cancer is the most common malignancy in females worldwide with estimated
incidence of 252.710 invasive breast cancer and 41.070 deaths expected in 2017 in the
United States alone [1]. In Sudan, breast cancer incidence is increasing. Its frequency
was 610 (10.01% of registered cancer cases) in 2003 and 1015 (16.7% of registered can-
cer cases) in 2010 as referred to Statistic Department at Khartoum Oncology Hospital.
Moreover, breast cancer showed high incidence in young and middle age group (27%
at 41-50 years old and 26% at group 31-40 years old) [2].
Iron is necessary for human life. Most functional iron is in the form of haemoglobin
and myoglobin, but a small, significant portion of iron is used to bind with cofactors
essential to basic metabolic oxidative and reduction reactions. The regulation of body
iron is complex and exquisitely done so as to preserve iron needed but not to allow
highly toxic excess [3].
Although iron is a crucial element for cells but in excess may be dangerous. Iron
overload is linked with an elevated risk for some malignant diseases, including breast
cancer [4]. Iron is necessary for cell proliferation and iron metabolism is influenced
by oestrogen hormones. Interactions between iron and oestrogen may synergistically
promote breast cancer [5].
Cancer patient suffers from many abnormalities. Females with breast cancer suffer
from anaemia which is related directly to cancer, such those patients when given
therapeutic iron to treat anaemia may impact with a prognosis of breast cancer.
A few published studies showed a relationship between serum iron, TIBC and trans-
ferrin saturation percent and breast cancer and they pointed to the need for more
studies.
This study is expected to raise the attention to the consideration of serum iron status
at the diagnosis and as a prognosticmarker of breast cancer.Whether high or low levels
were encountered, a balance should be taken for the best outcome of the patient.
2. Materials and Methods
This is a case-control study that measured serum iron, TIBC and transferrin saturation
percent in newly diagnosed breast cancer at Khartoum Oncology Hospital (KOH) and
apparently healthy Sudanese females in Khartoum State, in the period from February
to August 2015.
Females confirmed histopathologically to have breast cancer within one month of
the date of histopathology report regardless of the menopausal status, with no other
chronic condition or not under treatment with iron supplements which affect the result
DOI 10.18502/sjms.v12i3.915 Page 120
Sudan Journal of Medical Sciences Production and Hosting by Knowledge E
were included in this study. Breast cancer patients diagnosed histologically more than
one month, breast cancer patients under- radiation or hormonal or chemotherapy and
patients receiving therapeutic iron were excluded from this study.
The control group included apparently healthy females matched to patients in age
group and parity. Women not known to have any cancer, chronic illness, anaemia or
taking iron supplements were selected.
The samples size was set by using the formula:
𝑛 = 𝑁𝑁 + (𝑑2) (1)
𝑛 = sample size
𝑁 = total number of females newly diagnosed with breast cancer per year
𝑑 = degree of precision (0.05) [6].
According to the formula, sample size is 100 samples and was set to be 120
(50 as cases and 70 as controls).
Cases were selected using simple random sampling technique. The control group
was selected using stratified sampling technique from the 41 Primary Health Centers
(PHCs) distributed among the seven localities of Khartoum State. Data concerning
population size and PHCs were collected from the website of Ministry of Health –
Khartoum State.
Data were collected through an interview using a questionnaire which contains the
following variables: age, marital status, parity, menopausal status, chronic illness, the
presence of cancer, treatment, use of iron supplements. The date, type of breast cancer,
and histopathological grade were reported from the patients’ clinical records.
Five ml of the Blood were collected from the superficial vein in the antecubital fossa
from the study population under the sterile condition and collected in a plain container,
centrifuged to get serum and kept at -20 till the samples were analysed.
2.1. The Method of Serum Iron Measurement
Estimation of serum iron was performed using a manual method (IRON-FERROZINE)
[7] based on the fact that transferrin-bound ferric ions in the sample are released by
guanidinium and reduced to ferrous by means of an ascorbic acid. Ferrous ions react
with ferrozine forming a coloured complex that can be measured by a spectropho-
tometer (CECIL instrument, Cambridge England 1000 series) [7].
The procedure was briefly as follows:
Three test tubes were labelled (sample-sample blank-standard). 1.0 ml from work-
ing reagent was placed in a tube labelled with the sample and the standard. 1.0 ml from
reagent A was placed in the tube labelled with sample blank. 200𝜇L from the sample
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was added to the tube labelled with sample and sample blank. 200𝜇L from standard
was added to the tube labelled with the standard. All tubes were mixed thoroughly
and let stand for 5 minutes at room temperature. Absorbance (A) for all tubes was
read at 560 nm against distilled water.
Serum iron concentration was calculated using the following general formula:
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 =
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑏𝑙𝑎𝑛𝑘
𝐴 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 × 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
(2)
The Reference value in women is 50-170 𝜇g/dL [7].
2.2. The Method of Total Iron Binding Capacity Measurement
Estimation of total iron binding capacity (TIBC) was performed by using a manual
method (IRON-FERROZINE) with the following principle:
Excess of 𝐹𝑒+3 is added to the sample to saturate serum transferrin. Uncomplexed
𝐹𝑒+3 is precipitated with magnesium hydroxide carbonate and the iron bonded to
protein in the supernatant is then spectrophotometrically measured [7].
The procedure was briefly as follows:
1.0 ml from reagent A was placed in a clean dry test tube. 0.5 ml from the sample
was added. The test tube was mixed thoroughly and let stand for 5-30 minutes at
room temperature. One spoonful of reagent B was added. The test tube was mixed
thoroughly and let stand for 30-60 minutes at room temperature. The test tube was
centrifuged at a minimum 3000 round per minute for 10 minutes. The supernatant was
carefully collected [7]. The serum iron concentration in the supernatant was measured
using the kit of iron from Biosystems Company, Barcelona (Spain).
𝑇𝑜𝑡𝑎𝑙 𝑖𝑟𝑜𝑛 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (𝑇𝐼𝐵𝐶) =
𝑆𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 × 3
(3)
3 = dilution factor.
The reference value is 250-425 𝜇g/Dl in adults [7].
2.3. Calculation of Transferrin Saturation Percent




The reference value in women is 15-50% [7].
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2.4. Data Analysis
Data were computed and analysed using Statistical Package for Social Science (IBM
SPSS version 22.0) computer software. Pearson Chi-squire, Student t-test and One-
way ANOVA were used. P. value at 0.05 was considered statistically significant.
3. Results
The study was conducted on 120 samples, 50 breast cancer cases and 70 non-cancer
controls. The mean age of the studied case group was 47years and 42 years in the
control group with the most common age group 45-54 years and 35-44 years, respec-
tively, while the mean of parity number was 4 in both groups. There were 49.0(98.0%)
married females and 1.0 (2.0%) was single in the case group, 43.0(61.4%)married, 11.0
(15.7%) single, 8.0(11.4%) divorced and 8.0(11.4%) widow in the control group.
The mean of serum iron in the study group is shown in Table1.
The mean of serum iron in invasive ductal carcinoma 247.76 (𝜇g/dL), 188.00(𝜇g/dL)
in stromal sarcoma and 254.00(𝜇g/dL) in non-invasive ductal carcinoma.
Table (2) showed the mean of serum iron, mean of TIBC and mean of transferrin
saturation percent in different histopathological grades of breast carcinoma according
to Modified Bloom Richardson’s grading system.
Table (3) stated the mean of serum iron, mean of TIBC and mean of transferring
saturation percent in menopausal and non-menopausal breast cancer patients.
4. Discussion
It is known that iron is present throughout the body. Most physiologically active, but
some are stored for future use. The intracellular space of the liver and bone marrow
contains the majority of the stored iron. Iron is stored for the most part in the form of
ferritin, which is composed of iron and a protein called apoferritin, when apoferritin is
unavailable, iron is stored as hemosiderin [8].
Iron is an essential metal vital for living cells and may be the main culprit in tumour
immunosuppression. It plays a role in the different mechanisms and functions of
tumorigenesis [9]. It is required by a large number of heme and non-heme enzymes
and proteins, which have essential functions in oxygen transport and oxidative phos-
phorylation [10].
Preclinical and clinical models proved that iron metabolism is deregulated in breast
cancer [11]. Iron is a cofactor for ribonucleotide reductase, an enzyme that converts
ribonucleotides to deoxyribonucleotides for the synthesis and repair of DNA. Thus it is
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Case 50.0 244.30 151.598 0.000
Control 70.0 57.59 43.191
TIBC* (𝜇g/dL) Case 50.0 412.98 177.460 0.838




Case 50.0 61.08 41.523 0.000
Control 70.0 223.23 149.195
T 1: Serum iron concentration, TIBC, and transferrin saturation percent among the study population. N
= Number, *TIBC = Total Iron Binding Capacity.
a crucial element in DNA synthesis, and a constant supply of iron is required tomaintain
DNA activity [12]. Being highly proliferative, tumour cells need more iron and they
usually show high intracellular iron concentration [13, 14]. The growth of mammary
adenocarcinoma cell xenografts in rats was inhibited by low iron diet [15]. Moreover,
exposing the dividing tumour cells to different iron chelators inhibited proliferation and
lead to cell cycle arrest in in vitro as well as in vivo models [16–18].
The status of systemic iron is normally regulated by Hepcidin, which is a liver peptide
hormone. It blocks iron release from enterocytes into plasma [19]. In cultured breast
cancer cells, the expression of ferroportin proved to be negatively regulated by hep-
cidin through a post-transcriptional mechanism. Moreover, since the concentration of
hepcidin is higher in tumour cells than in normal cells, the higher hepcidin/ferroportin
ratio increases the expressionof ferritin and subsequently, raises the iron labile pool in
cancer cells [20].
Though the mechanisms of miss-regulated expression of iron-related genes are
not clearly known, the fundamental signalling of iron homoeostasis, the hepcidin-
ferroportin axis was found to promote the growth of breast cancer when disordered
[21]. Zhang et al found high levels of serum hepcidin in patients with breast cancer and
greatly reduced concentration of tumour ferroportin in breast tumours, especially in
malignant tumours, compared to adjacent tissues [19]. Further, they verified that high
levels of ferroportin inhibited cell proliferation in vitro and in vivo by knocking down
the expression of tumour hepcidin. So, to lock up breast cancer growth, targeting the
hepcidin-ferroportin signalling pathway would signify a talented therapeutics [19].
Furthermore, high ferritin level in some solid tumours, including breast cancer, has
been reported by several studies [22]. Pusatcioglu et al reported the significantly
higher level of iron accumulation in colonic tissue of colorectal cancer patients com-
pared to controls [21]. Moreover, an independent relationship between the level of
serum ferritin and hepatocellular carcinoma was found in patients with chronic liver
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parameter Histopathological
grade*
N mean SD deviation P. value
Serum iron
(𝜇g/dL)
I 3.0 248.67 147.873 0.883
II 31.0 252.06 168.055
III 16.0 228.44 123.601
TIBC
(𝜇g/dL)
I 3.0 343.00 104.446 0.019
II 31.0 467.10 185.205





I 3.0 71.00 28.844 0.531
II 31.0 55.85 37.209
III 16.0 69.38 51.015
T 2: Serum iron concentration, TIBC and transferrin saturation percent in different histopathological
grades of breast cancer among respondents. N = Number, TIBC = Total Iron Binding Capacity, *Modified
Bloom Richardson’s grading system.
parameters Menopausal
status
N Mean SD deviation P. value
Serum iron
(𝜇g/dL)
Yes 23.0 423.0 150.40 0.691
NO 27.0 403.0 200.03
TIBC (𝜇g/dL) Yes 23.0 272.0 178.48 0.224




Yes 23.0 62.0 34.88 0.691
NO 27.0 60.0 47.09
T 3: Correlation of menopausal status and concentration of serum iron, TIBC and transferrin saturation
percent in breast cancer patients. N = Number, TIBC = Total Iron Binding Capacity.
disease due to viruses [23]. A relative risk (RR) of1.03; 95% CI, 0.97-1.09 for breast
cancer for an increase of 1 mg/day of heme iron consumption was reported. The
greater consumption of heme iron, but not serum ferritin has shown a tendency toward
a positive association with cancer risk [24].
On the other hand, there are reliable publications linking the mutations of C282Y
and H63D in the High Iron Fe (HFE) which is encoded by the hemochromatosis gene
that causes iron overload (heterozygous mutations) and hereditary hemochromatosis
of type I (homozygous mutations) to the risk of developing breast cancer (Odds ratios
ranging between 2.05 and 4.4) [25, 26]. However, a study on pre-menopausal women
did not demonstrate any association between HFE single nucleotide polymorphysm
SNPs and risk of breast cancer [27].
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During the early steps of carcinogenesis the gene encoding human ferritin (FTH)
is found to be up-regulated [28]. Interestingly, the ectopic expression of microRNA
200b that negatively regulates FTH in breast cancer cells has shown a better response
to doxorubicin in vitro [29]. The iron labile the pool is increased through inhibition of
ferroportin expression and stimulation of ferritin expression through iron regulatory
protein 2 (IRP2), which is overexpressed in breast cancer, hence playing an early role
in cancer-related iron overload [30].
In spite of its importance for cell respiration, iron can cause oxidative stress and DNA
damage [11]. Fe2+ catalyses the production of very active hydroxyl radicals, through
the Fenton and Haber–Weiss reactions, that can form DNA adducts and initiate carcino-
genesis [11]. Furthermore, breast carcinogenesis is promoted by stimulating tumour
growth through activation of oestrogen receptors by oestrogens and also by the pro-
duction of genotoxic metabolites of estradiol. DNA adducts can further be formed by
catechols and their quinoline derivatives and they can favour the occurrence of muta-
tions. The growth of breast tumours is stimulated by oxidised derivatives of oestro-
gens [31]. The oxidative stress produced by iron could favour the production of these
genotoxic metabolites [11].
Physiologically, hepcidin expression is negatively regulated by increased erythro-
poiesis [32] or hypoxia and contrariwise, it is inspired by the high level of circulating
iron and by inflammation. The expression of hepcidin is induced by lipopolysaccharides
(LPS) and interleukin 6 (IL-6) during inflammation, which activates hepcidin synthesis
through the signal transducer and activator of transcription 3 (STAT3) pathway [32].
Thus, iron overload is incriminated in carcinogenesis via different mechanisms
including the assembly of free radicals, development of oxidative stress, the interac-
tion with other carcinogens and genetic mutations in addition to immunomodulation
[11].
In this study 120 females, 50 as caseswith breast cancer and 70 as non-breast cancer
controls were involved; for all those women serum iron, TIBC and transferrin saturation
percent were measured or calculated. It revealed a statistically significant increase in
the mean of serum iron and decrease in transferrin saturation percent in women with
breast cancer while no significant variation in the mean of TIBC between case and
control groups. The finding of Pavithra et al in their study is similar to this study in
serum iron level; they found significantly high levels of serum iron in 54 female patients
with breast cancer when compared to 54 female controls [33].
In the study conducted by Dhankha et al, it was found that the serum iron level, TIBC
and transferrin saturation percent were significantly elevated in sixty breast cancer
patients as compared to thirty healthy controls [34] . Though agree with results con-
cerning serum iron but disagree in the level of TIBC and transferrin saturation percent
in the current study. This could be attributed to the methods used.
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Transferrin (TF), a bi-lobed glycoprotein is the chief iron transport protein in the
mammalian blood [35]. There is no significant variation in the mean of serum iron and
transferrin saturation percent according to the type of breast cancer and histopatho-
logical grade in this study, but there is a significant increase in the mean of TIBC in
females with grade II. That is disagreeing with Dhankhar et al study in which they
reported that patients with advanced disease showed greater values as compared to
an early stage, as patients in the current study were in the early stage of the disease
because all patients were taken in this study within one month of histopathology
report. Nevertheless, there is an agreement regarding TIBC [34].
Interestingly, Dhankhar et al analysed iron, ferritin and TIBC in thirty patients with
early stage, thirty with advanced stage breast carcinoma before and after treatment
and the results were related to thirty healthy controls. Breast cancer patients showed
significantly higher levels of all the three parameters as related to healthy controls
and patients with advanced disease showed greater values as when matched to early
stage disease. Additionally, there is a decrease in these levels following treatment
significantly in patients with complete response [34]. Therefore, serum analyses of
iron, ferritin and TIBC may be of prognostic help in assessing the severity of breast
cancer.
Furthermore, a cohort study done byWen et al in 309,443 adults in Taiwan in women
who had no history of cancer had serum iron levels tested at the time of recruitment.
The authors associated the firstly measured iron levels with subsequent cancer risk
by connecting individuals with the National Cancer Registry and National Death File.
The relationship between serum iron and cancer risk was a J-shaped one, with higher
cancer risk at both ends, either at lower than 60 mg/dL or higher than 120 mg/dL [36].
High serum iron could be either a common disorder or/and a biochemical marker of
increased risk for breast cancer [36].
On the other hand, there is no significant variation in the mean of transferrin sat-
uration percent, TIBC and serum iron in menopausal and non- menopausal female
in this study. Nevertheless, another study reported that serum iron is a weak risk
factor in menopausal women (Hazard ratio of standardized SI 1.09 (95% CI 1.02-1.015)
[37]. High levels of stored iron may act as a risk factor for mortality due to cancer
in postmenopausal women and may be attributed by a buildup of stored iron among
women after menopause [37].
The limitation of this study includes small sample size besides the use of the manual
methods. More studies should be undertaken with adequate sample size and more
advanced method for measurement of serum iron and TIBC must be used.
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5. Conclusion
In spite of its limitations, this study concluded that there is a statistically significant
difference in serum iron (increased) and transferrin saturation percent (decreased)
between Sudanese females newly diagnosed with breast cancer and apparently
healthy females. While there is no significant difference in TIBC between Sudanese
females newly diagnosed with breast cancer and apparently healthy females. Serum
iron, TIBC and transferrin saturation percent did not vary in regard to the type of breast
cancer and menopausal status. TIBC but not serum iron and transferrin saturation
percent vary significantly according to histopathological grade. The results of this
study affirm the previous studies that serum iron and transferrin saturation percent
may be helpful as biochemical risk markers for breast cancer and that TIBC may act as
a predictor of disease grade.
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